中国草药在儿科瘤学:对生存和毒性的影响 - - 一个元分析
Ximeng Li1, Gefu Cai1, Márk Viktor Hernádfői2
1Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
概括
中国草药 (CHM) 显著改善了儿科癌症患者的缓解率和免疫功能. 它还减少了治疗毒性,如感染和恶心,支持传统疗法.
科学领域:
- 综合性瘤学 综合性瘤学
- 儿科血液学/瘤学
- 基于证据的医学基于证据的医学.
背景情况:
- 儿童癌症治疗涉及具有显著副作用的侵略性疗法.
- 中国草药 (CHM) 显示出减轻这些不良影响的潜力.
- 需要严格的证据来验证CHM在基于证据的儿科癌症护理中的作用.
研究的目的:
- 评估CHM在儿科瘤学中作为常规癌症治疗的辅助药物的疗效.
- 评估CHM对减少治疗相关毒性的影响.
- 确定CHM对儿童癌症患者免疫功能和缓解率的影响.
主要方法:
- 随机对照试验 (RCT) 的系统审查和元分析.
- 搜索了英语和中文数据库,用于接受常规治疗的儿科瘤患者.
- 提取了关于缓解率,免疫参数和不良事件的数据;使用几率比率 (OR) 和平均差异 (MD) 进行聚合.
主要成果:
- 医疗疗疗法改善了完全缓解率 (OR: 1.82) 和部分缓解率 (OR: 2.92).
- 增强的免疫参数,包括CD4+计数 (MD:7.30) 和CD4+/CD8+比 (MD:0.27).
- 减少了感染率 (OR:0.37),恶心/吐 (OR:0.43),以及心电图异常 (OR:0.39).
结论:
- 医疗瘤治疗在儿科瘤学中显示出作为一种补充疗法的前景.
- CHM有效降低与常规癌症治疗相关的毒性,并支持免疫功能.
- 进一步的大规模,多中心试验是必要的,以标准化CHM整合到儿科癌症护理.
相关概念视频
01:21Cancer Survival Analysis
626
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
626
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
01:20Comparing the Survival Analysis of Two or More Groups
531
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
531